These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12652148)

  • 1. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
    Newby LK; Harrington RA; Bhapkar MV; Van de Werf F; Hochman JS; Granger CB; Simes RJ; Davis CG; Topol EJ; Califf RM; Moliterno DJ;
    J Thromb Thrombolysis; 2002 Aug; 14(1):33-42. PubMed ID: 12652148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
    Lee MS; Wali AU; Menon V; Berkowitz SD; Thompson TD; Califf RM; Topol EJ; Granger CB; Hochman JS
    J Thromb Thrombolysis; 2002 Oct; 14(2):91-101. PubMed ID: 12714828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
    Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E
    Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators.
    Becker RC; Ball SP; Eisenberg P; Borzak S; Held AC; Spencer F; Voyce SJ; Jesse R; Hendel R; Ma Y; Hurley T; Hebert J
    Am Heart J; 1999 Jan; 137(1):59-71. PubMed ID: 9878937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction].
    Shalaev SV; Shava VP; Petrik ES; Pushnikova MA; Zhuravleva TD
    Kardiologiia; 2005; 45(10):27-30. PubMed ID: 16234765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
    Granger CB; Hirsch J; Califf RM; Col J; White HD; Betriu A; Woodlief LH; Lee KL; Bovill EG; Simes RJ; Topol EJ
    Circulation; 1996 Mar; 93(5):870-8. PubMed ID: 8598077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the aPTT and clinical events in acute coronary syndromes treated with unfractionated heparin.
    Mitrovska S; Jovanova S
    Bratisl Lek Listy; 2006; 107(11-12):422-5. PubMed ID: 17425158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated partial thromboplastin time (aPTT) monitoring to achieve therapeutic anticoagulation before and after introducing a nomogram for adjunctive heparin treatment with thrombolytic therapy for acute myocardial infarction.
    Chamuleau SA; de Winter RJ
    Int J Cardiol; 1998 Dec; 67(3):241-6. PubMed ID: 9894705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
    Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
    Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers.
    Cannon CP; Dingemanse J; Kleinbloesem CH; Jannett T; Curry KM; Valcke CP
    Circulation; 1999 Feb; 99(6):751-6. PubMed ID: 9989959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries.
    Gilchrist IC; Berkowitz SD; Thompson TD; Califf RM; Granger CB
    Am Heart J; 2002 Jul; 144(1):73-80. PubMed ID: 12094191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service.
    Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S
    Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.
    Global Organization Network (PARAGON)-B Investigators
    Circulation; 2002 Jan; 105(3):316-21. PubMed ID: 11804986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing methods of establishing the aPTT therapeutic range of heparin.
    Liepman CI; Koerber JM; Mattson JC; Westley SJ; Smythe MA
    Ann Pharmacother; 2003 Jun; 37(6):794-8. PubMed ID: 12773063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.